deltatrials
Completed PHASE3 NCT00035490

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

Sponsor: Forest Laboratories

Conditions Arrhythmia
Interventions Azimilide Dihydrochloride placebo
Updated 7 times since 2017 Last updated: Sep 30, 2011 Started: Sep 30, 2001 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This PHASE3 trial investigates Arrhythmia and is currently completed. Forest Laboratories leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Forest Laboratories
Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands, Bad Bevensen, Germany, Bad Nauheim, Germany, Bad Oeynhausen, Germany, Baltimore, United States, Barcelona, Spain, Bari, Italy, Berlin, Germany, Beverly Hills, United States, Bonn, Germany and 118 more location s